A Phase 3 interventional study of meloxicam/cyclobenzaprine hydrochloride and meloxicam - Movatec® in Acute Lumbago, sponsored by Eurofarma Laboratorios S.A.. Withdrawn at 11 sites in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-03.
Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.
Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 119th largest by enrollment of the 122 interventional ones that give a count, is one of 12 that started in 2013, is one of 9 in phase 3, and was the 25th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of Bahia · Sites in Brazil
Ages 18–55
Gabriela Souza de Vasconcelos · Sites in Brazil
Ages 18–59
University of Nove de Julho · Sites in Brazil
Ages 18–70
University of Nove de Julho · Sites in Brazil
Ages 18–65
Centro Universitário Augusto Motta · Sites in Brazil
Ages 65+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 12 started in 2013.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 66 across the 122 interventional studies, 100 across the 3 observational. Of the 75 that completed or were terminated, 5 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 125 have an industry lead sponsor. The 10 most frequent:
Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.
Eurofarma Laboratorios S.A. has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Low Back Pain with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459376Universidade Federal do Rio Grande do NorteEffect of Dry Cupping Therapy Associated With the McKenzie Method in Patients With Chronic Low Back Pain | 2027-01-01 |
| NCT07639216Centro Universitário Augusto MottaNeuroscience Education and Spinal Manipulation on Health Locus of Control in Low Back Pain | 2027-07 |
| NCT05480982Centro Universitário Augusto MottaCognitive Functional Therapy Compared With Pilates in Elderly Patients With Chronic Low Back Pain | 2027-07 |
| NCT06651099University of BrasiliaTrial-based Economic Evaluation of a Mobile Health Intervention for Individuals With Chronic Non-specific Low Back Pain | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 125 studies in Low Back Pain with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.
To assess the efficacy and tolerability of a new drug containing the combination meloxicam and cyclobenzaprine in the treatment of acute lumbago, compared to the same components alone.
Some eligibility criteria:
Have a normal X-ray of the lumbar spine for the age; Have a baseline score in the VAS higher than or equal to 40 mm
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: meloxicam - Movatec®
Drug: cyclobenzaprine - Miosan®
Drug: meloxicam/cyclobenzaprine hydrochloride
Drug pages: Meloxicam · Cyclobenzaprine
two oral capsules a day during approximately 07 days
two oral tablet a day during approximately 07 days
two oral tablet a day during approximately 07 days
Pain Reduction
Compare the treatment groups for the efficacy in pain reduction, 3 days after the administration of study drugs, when compared to the baseline assessment.
Time frame: Pain reduction 3 days after the administration of study drugs
Frequency of rescue medication use
Assessment of frequency of rescue medication use, as well as the proportion of patients during study treatment;
Time frame: During study treatment, an expected average of 7days
The record gives a start of May 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meloxicam · Cyclobenzaprine